A phase 1 trial of XK469: Toxicity profile of a selective topoisomerase IIβ inhibitor
A phase 1 trial of XK469: Toxicity profile of a selective topoisomerase IIβ inhibitor
About this item
Full title
A phase 1 trial of XK469: Toxicity profile of a selective topoisomerase IIβ inhibitor
Author / Creator
Journal title
Investigational new drugs, 2007-04, Vol.25 (2), p.147-154
Language
English
Formats
More information
Scope and Contents
Contents
Purpose: XK469, a member of the quinoxaline family of antitumor agents, is believed to be unique in its ability to selectively target topoisomerase II beta . Based on encouraging pre-clinical data, a phase I trial was conducted to determine the dose limiting toxicity (DLT) and the maximum tolerated dose (MTD).Methods: A 2B accelerated titration sch...
Alternative Titles
Full title
A phase 1 trial of XK469: Toxicity profile of a selective topoisomerase IIβ inhibitor
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_proquest_miscellaneous_20795919
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_miscellaneous_20795919
Other Identifiers
ISSN
0167-6997
E-ISSN
1573-0646
DOI
10.1007/s10637-006-9024-5
How to access this item
Log in as a Library member
